Dr. Reddy’s Q4 & FY23 Financial Results

HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2023. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005650/en/

Q4 FY23 Sales Mix (Graphic: Business Wire)

Q4 FY23 Sales Mix (Graphic: Business Wire)

Q4 Performance Summary   FY23 Performance Summary
     
Rs. 6,297 Cr   Rs. 24,588 Cr
Revenue   Revenue
[Up: 16% YoY; Down 7% QoQ]   [Up: 15% YoY]
     

57.2%

 

56.7%

Gross Margin   Gross Margin
[Q4 FY22: 52.9%; Q3 FY23: 59.2%]   [FY22: 53.1%]
     
Rs. 1,799 Cr   Rs. 6,803 Cr
SGNA expenses   SGNA expenses
[28.6% of Revenues]   [27.7% of Revenues]
     
Rs. 537 Cr   Rs. 1,938 Cr
R&D expenses   R&D expenses
[8.5% of Revenues]   [7.9% of Revenues]
     
Rs. 1,631 Cr   Rs. 7,308 Cr
EBITDA   EBITDA
[25.9% of Revenues; Up: 26% YoY; Down: 17% QoQ]   [29.7% of Revenues; Up: 42% YoY]
     
Rs. 1,326 Cr*   Rs. 6,037 Cr*
Profit before Tax   Profit before Tax
[Up: 434% YoY; Down: 19% QoQ]   [Up: 87% YoY]
     
Rs. 959 Cr   Rs. 4,507 Cr
Profit after Tax   Profit after Tax
[Up: 996% YoY; Down: 23% QoQ]   [Up: 91% YoY]

* Excluding impairments in current & previous periods, Q4 FY 23 PBT is Rs. 1,380 Cr (growth of 38% YoY) and FY 23 PBT is Rs. 6,107 Cr (growth of 53% YoY)

Commenting on the results, Co-Chairman & MD, G V Prasad said: “FY 23 has been a year of record sales, profits and cash flow, driven by our performance in US Generics. We progressed well in our productivity and sustainability agenda. We will continue to deliver on our purpose, invest in growth drivers and promote a culture that is innovative and collaborative ensuring the future of our business.”

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19

Dr. Reddy’s Laboratories Limited and Subsidiaries

 

Consolidated Income Statement

           

Particulars

Q4 FY23

Q4 FY22

YoY
Gr %

Q3 FY23

QoQ
Gr%

($)

(Rs.)

($)

(Rs.)

($)

(Rs.)

Revenues

766

62,968

661

54,368

16

824

67,700

(7)

Cost of Revenues

328

26,971

312

25,625

5

336

27,607

(2)

Gross Profit

438

35,997

350

28,743

25

488

40,093

(10)

Operating Expenses

               

Selling, General & Administrative expenses

219

17,992

191

15,674

15

219

17,981

0

Research and Development expenses

65

5,366

53

4,326

24

59

4,821

11

Impairment of non-current assets

7

540

91

7,515

(93)

2

134

303

Other operating (income)/expense

(3)

(281)

(4)

(291)

(3)

9

732

(138)

Results from operating activities

151

12,380

18

1,519

715

200

16,425

(25)

Net finance (income)/expense

(10)

(799)

(10)

(859)

(7)

2

139

(675)

Share of profit of equity accounted investees

(1)

(76)

(1)

(105)

(28)

(1)

(60)

27

Profit before income tax

161

13,255

30

2,483

434

199

16,346

(19)

Income tax expense

45

3,663

20

1,608

128

47

3,875

(5)

Profit for the period

117

9,592

11

875

996

152

12,471

(23)

                 

Diluted Earnings Per Share (EPS)

0.70

57.62

0.06

5.26

995

0.91

74.95

(23)

As % to revenues

 

Q4 FY23

 

Q4 FY22

   

Q3 FY23

Gross Profit

 

57.2

 

52.9

   

59.2

SG&A

 

28.6

 

28.8

   

26.6

R&D

 

8.5

 

8.0

   

7.1

EBITDA

 

25.9

 

23.9

   

29.0

PBT

 

21.1

 

4.6

   

24.1

PAT

 

15.2

 

1.6

   

18.4

EBITDA Computation

           

Particulars

Q4 FY23

 

Q4 FY22

 

Q3 FY23

($)

(Rs.)

 

($)

(Rs.)

 

($)

(Rs.)

Profit before Income Tax

161

13,255

 

30

2,483

 

199

16,346

Interest (income) / expense - Net*

(8)

(673)

 

0

24

 

(1)

(93)

Depreciation

27

2,213

 

25

2,039

 

27

2,245

Amortization

12

977

 

11

920

 

12

1,026

Impairment

7

540

 

91

7,515

 

2

134

EBITDA

198

16,312

 

158

12,980

 

239

19,658

* Includes income from Investments

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19

Revenue Mix by Segment

           

Segment

Q4 FY23

Q4 FY22

YoY
Gr %

Q3 FY23

QoQ
Gr %

(Rs.)

(Rs.)

(Rs.)

Global Generics

54,257

46,118

18

59,241

(8)

North America

25,321

19,971

27

30,567

(17)

Europe

4,960

4,444

12

4,303

15

India

12,834

9,689

32

11,274

14

Emerging Markets

11,142

12,013

(7)

13,097

(15)

Pharmaceutical Services and Active Ingredients (PSAI)

7,787

7,557

3

7,758

0

Others

924

693

33

701

32

Total

62,968

54,368

16

67,700

(7)

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19

Dr. Reddy’s Laboratories Limited and Subsidiaries

Consolidated Income Statement

       

Particulars

FY23

FY22

Gr

%

($)

(Rs.)

%

($)

(Rs.)

%

Revenue

2,992

2,45,879

100.0

2,608

2,14,391

100.0

15

Cost of revenues

1,296

1,06,536

43.3

1,223

1,00,551

46.9

6

Gross profit

1,695

1,39,343

56.7

1,385

1,13,840

53.1

22

Operating Expenses

             

Selling, General & Administrative expenses

828

68,026

27.7

755

62,081

29.0

10

Research and Development expenses

236

19,381

7.9

213

17,482

8.2

11

Impairment of non-current assets

9

699

0.3

92

7,562

3.5

(91)

Other operating income

(72)

(5,907)

(2.4)

(34)

(2,761)

(1.3)

114

Results from operating activities

695

57,144

23.2

359

29,476

13.7

94

Net finance income

(35)

(2,853)

(1.2)

(26)

(2,119)

(1.0)

35

Share of profit of equity accounted investees

(5)

(370)

(0.2)

(9)

(703)

(0.3)

(47)

Profit before income tax

734

60,367

24.6

393

32,298

15.1

87

Income tax expense

186

15,300

6.2

106

8,730

4.1

75

Profit for the period

548

45,067

18.3

287

23,568

11.0

91

               

Diluted EPS

3.30

270.85

 

1.72

141.69

 

91

EBITDA Computation

     

Particulars

FY23

FY22

($)

(Rs.)

($)

(Rs.)

Profit before Income Tax

734

60,367

393

32,298

Interest income - Net*

(8)

(621)

(3)

(284)

Depreciation

105

8,614

99

8,152

Amortization

49

4,022

45

3,672

Impairment

9

699

92

7,562

EBITDA

889

73,081

625

51,400

* Includes income from Investments

       

Key Balance Sheet Items

       

Particulars

As on 31st Mar 2023

As on 31st Dec 2022

As on 31st Mar 2022

($)

(Rs.)

($)

(Rs.)

($)

(Rs.)

Cash and cash equivalents and other investments

760

62,456

610

50,164

584

48,033

Trade receivables (current & non-current)

882

72,486

913

75,046

813

66,818

Inventories

592

48,670

600

49,326

619

50,884

Property, plant and equipment

809

66,462

791

64,996

756

62,169

Goodwill and Other Intangible assets

427

35,094

431

35,401

385

31,664

Loans and borrowings (current & non-current)

164

13,472

215

17,663

412

33,845

Trade payables

322

26,444

317

26,023

311

25,572

Equity

2,810

2,30,991

2,680

2,20,273

2,318

1,90,527

All amounts in millions, except EPS. All US dollar amounts based on convenience translation rate of 1 USD = Rs. 82.19

Revenue Mix by Segment [year on year]

       

Segment

FY23

FY22

Gr

%

($)

(Rs.)

%

($)

(Rs.)

%

Global Generics

2,601

2,13,768

86.9%

2,180

1,79,170

83.6%

19%

North America

1,237

1,01,704

41.4%

911

74,915

34.9%

36%

Europe

214

17,603

7.2%

202

16,631

7.8%

6%

India

595

48,932

19.9%

510

41,957

19.6%

17%

Emerging Markets

554

45,529

18.5%

556

45,667

21.3%

0%

Pharmaceutical Services and Active Ingredients (PSAI)

354

29,069

11.8%

374

30,740

14.3%

-5%

Others

37

3,042

1.2%

55

4,481

2.1%

-32%

Total

2,992

2,45,879

100.0%

2,608

2,14,391

100.0%

15%

Revenue Analysis [Q4 FY23 and FY23]

Global Generics (GG)

  • FY23 revenue for GG segment at Rs. 213.8 billion higher by 19% over FY22. This growth was driven by North America, Europe and India, while Emerging markets remained flat.
  • Q4 revenue at Rs. 54.3 billion, YoY growth of 18% and QoQ decline of 8%. YoY growth was driven by growth in North America, Europe and India markets; however, partially impacted due to a decline in revenues in Emerging Markets. QoQ decline was mainly due to decline in North America and Emerging Markets, partially offset by growth in Europe and India

North America

  • FY23 revenue from North America Generics for the year at Rs. 101.7 billion, YoY growth of 36%. The growth was contributed by new launches, scale up of existing products and favorable forex rates movement, which was partially offset by price erosion.
  • Q4 revenue at Rs. 25.3 billion, YoY growth of 27% and QoQ decline of 17%. YoY growth was primarily on account of new product launches and favorable forex rates movement, partly offset by price erosion. QoQ decline was due to fluctuation in demand for our new launches.
  • During the quarter, we launched 6 new products – Difluprednate, Lurasidone Tablets, Lubiprostone Capsules, Sunitinib Capsules, Nelarabine Injection and Timolol Gel. This takes our full year launch count to 25 products.
  • During the year, we filed 12 new Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA). As of 31st March 2023, cumulatively 86 generic filings are pending for approval with the USFDA (81 ANDAs and 5 NDAs under 505(b)(2) route). Out of the pending 86 ANDAs, 45 are Para IVs, and we believe 18 have ‘First to File’ status.

Europe

  • FY23 revenue from Europe at Rs. 17.6 billion. YoY growth of 6%, driven by volume traction in base business and new product launches, which was partially offset by price erosion in some of our products.
  • Q4 revenue at Rs. 5.0 billion, YoY growth of 12% and QoQ growth of 15%. YoY growth was primarily on account of new product launches and traction in base business volumes, partly offset by price erosion in the base business. QoQ growth was driven by traction in base business volumes and favourable forex rates movement.

India

  • FY23 revenue from India at Rs. 48.9 billion. YoY growth of 17% was primarily attributable to increase in prices of our existing products, along with additional revenues from the launch of new products. The growth was also aided by divestment of a few non-core brands during the year. During the year, we launched 9 new brands in India.
  • Q4 revenue at Rs. 12.8 billion, YoY growth of 32% and QoQ growth of 14%. YoY growth primarily driven by favorable price variance, new product launches, and non-core brand divestments while QoQ growth was primarily due to divestment of a few non-core brands, partially offset by decline in volumes of some of our products.

Emerging Markets

  • FY23 revenue from Emerging Markets at Rs. 45.5 billion, remained flat over the previous year. However, this grew by 13% adjusted for the covid related product sales and divestment income realized in the last year.
    • Revenue from Russia for the year at Rs. 21.2 billion, YoY growth of 2% impacted due to higher base of FY 22, which included revenues from divestment of few non-core brands. The base business grew by 11% net of divestment income, driven by favorable price variance and beneficial forex rates movement, partially offset by a decrease in volumes.
    • Revenue from other CIS countries and Romania for the year at Rs. 8.6 billion, YoY growth of 4%. Growth was on account of favorable price variance, partly offset by a decrease in volumes of base business and adverse movement in forex rates.
    • Revenue from Rest of World (RoW) territories for the year at Rs. 15.7 billion, YoY decline of 5% primarily on account of revenues from covid related products in the FY 22. The revenues were also impacted by an adverse price variance, partly offset by new product launches.
  • Q4 revenue at Rs. 11.1 billion, YoY decline of 7% and QoQ decline of 15%.
    • Revenue for Russia for Q4 at Rs. 5.2 billion, both YoY and QoQ decline of 24%. YoY decline was mainly attributable to divestment income & higher channel inventory in Q4 of last year. QoQ decline was primarily due to reduction in base business volumes and adverse forex rates movement.
    • Revenue from other CIS countries and Romania for the quarter are Rs. 2.3 billion, remained flat YoY while showing an increase of 2% QoQ. Benefits from favorable price variance were set off with reduction in base business volumes.
    • Revenue from Rest of World (RoW) territories for Q4 at Rs. 3.7 billion, YoY growth of 28% and QoQ decline of 8%. The YoY growth was primarily driven by an increase in base business volumes, new product launches and favorable forex rates movement, partially offset by adverse price variance. QoQ decline was mainly due to adverse price variance and reduction in base business volumes.

Pharmaceutical Services and Active Ingredients (PSAI)

  • FY23 revenue from PSAI at Rs. 29.1 billion. YoY decline of 5%. The decline was mainly on account of decline in base business volumes and price erosion in some of our products, partially offset by new product launches and favorable forex rate movements. FY22 included higher contribution from sales of covid related portfolio.
  • Q4 revenue at Rs. 7.8 billion, with growth of 3% YoY, while it remained flat QoQ. YoY growth was primarily driven by new product launches and favourable forex rates movement. These were offset by a reduction in base business volumes and adverse price variance.
  • During the year, we have filed 12 DMFs in the US, of which 7 DMFs were filed in Q4FY23.

Income Statement Highlights:

  • FY 23 gross margin at 56.7%, an increase of ~360 bps over previous year. The increase was driven by new product sales of certain products with higher gross margins, higher government incentives and favourable foreign exchange. This was partially offset with price erosion in certain of our products, primarily in the United States and Europe. The gross profit margin for GG and PSAI business segments are at 62.1% and 16.2% respectively.

    Q4 gross margin at 57.2% (GG: 61.7%, PSAI: 25.2%). Gross margin increased by ~430 bps YoY, while it declined by ~210 bps QoQ. YoY increase was driven by new product sales of certain products with higher gross margins, and favourable foreign exchange, partially offset by price erosion, primarily in United States and Europe. QoQ decline was primarily due to lower government incentives and product mix, which was partly offset by income from divestment of non-core brands.
  • Selling, general & administrative (SG&A) expenses for FY23 at Rs. 68.0 billion, an increase of 10% on a YoY basis. SG&A as a % to sales for FY23 was 27.7%, a decline of 130 basis points over FY22. SG&A expenses for Q4 at Rs. 18.0 billion, YoY increase of 15% and remained flat QoQ. The SG&A spend increase is largely on account of investments in sales & marketing and adverse impact of forex rates.
  • Impairment charge for FY23 at Rs. 0.7 billion and for Q4 at Rs. 0.5 billion. This is mainly due to decrease in market potential of products acquired from Nimbus Health GmbH and certain other product-related intangibles due to adverse market conditions.
  • Research & development (R&D) expenses in FY23 at Rs. 19.4 billion. As % to Revenues – FY23: 7.9% | FY22: 8.2%. Q4 R&D expenses at Rs. 5.4 billion, 8.5% of revenue. We continue our focus on investing in R&D to build a healthy pipeline of new products across our markets for both small molecules and biosimilars.
  • Other operating income for FY23 at Rs. 5.9 billion compared to Rs. 2.8 billion in FY22. The net other income was higher primarily on account of recognition of income of Rs. 5.6 billion from a settlement agreement, with Indivior Inc., Indivior UK Limited, and Aquestive Therapeutics, Inc., resolving all claims between the parties relating to the Company’s generic buprenorphine and naloxone sublingual film. Other operating income for Q4 was Rs. 0.3 billion.
  • Net Finance income for FY23 at Rs. 2.9 billion compared to Rs. 2.1 billion in FY22. The increase is primarily on account of higher foreign exchange gain in current year as compared to FY22 and increase in profit on sale of mutual funds compared to FY22. Net finance income in Q4 was Rs. 0.8 billion.
  • Profit before Tax for FY23 at Rs. 60.4 billion, YoY growth of 87%. Profit before Tax for Q4 is at Rs. 13.3 billion.
  • Profit after Tax for FY23 at Rs. 45.1 billion and for Q4 at Rs. 9.6 billion. The effective tax rate for the year has been 25.3% as compared to 27.0% in FY22, due to changes in the Company’s jurisdictional mix of earnings. The effective tax rate for the quarter has been at 27.6% as compared to 64.8% in Q4FY22. The previous year ETR was higher due to impairment charge impact.
  • Diluted earnings per share for FY23 is Rs. 270.9. Diluted earnings per share for Q4 is Rs. 57.6.

Other Highlights:

  • EBITDA for FY23 at Rs. 73.1 billion and the EBITDA margin is 29.7%. EBITDA for Q4 at 16.3 billion and the EBITDA margin at 25.9%.
  • Capital expenditure for FY23 at Rs. 11.3 billion. Capital expenditure for Q4 at Rs. 2.6 billion.
  • Free cash-flow for FY23 at Rs. 40.1 billion and for Q4 it at Rs. 16.0 billion.
  • Net cash surplus for the company at Rs. 50.5 billion as on March 31, 2023.
  • The Board has recommended payment of a dividend of Rs. 40 per equity share of face value Rs 5/- each (800% of face value) for the year ended March 31, 2023 subject to approval of the members of the company.

All amounts in millions, except EPS

About key metrics and non-GAAP Financial Measures

This press release contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts, as the case may be, from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in this press release.

All amounts in millions, except EPS

Reconciliation of GAAP measures to Non-GAAP measures

   
     

Free Cash Flow

   
     
 

Three months Ended March 31, 2023

Year Ended

March 31, 2023

Net cash generated from operating activities

23,376

69,587

Less:

   

Taxes

(3,697)

(10,714)

Investments in PPE and Intangibles

(3,722)

(18,782)

Free Cash Flow

15,957

40,091

Operating working capital

   
 

Year Ended

March 31, 2023

Inventories

48,670

Trade Receivables

72,485

Less:

 

Trade Payables

26,444

Operating Working Capital

94,711

Net cash surplus

 
   
 

Year Ended

March 31, 2023

Cash and cash equivalents

5,779

Investments

56,678

Short-term borrowings

(7,390)

Long-term borrowings, current portion

(4,804)

Less:

 

Restricted cash balance

89

Lease liabilities (included in Long-term

borrowings, current portion)

(1,004)

Equity Investments

(included in Investments)

716

Net Cash Surplus

50,462

All amounts in millions, except EPS

Computation of Return on Capital Employed

 
   
 

Year Ended

March 31, 2023

Profit before tax

60,367

Less:

 

Interest and Investment Income

(Excluding forex gain/loss)

627

Earnings Before Interest and taxes [A]

59,740

   

Average Capital Employed [B]

1,72,602

   

Return on Capital Employed (A/B) (Ratio)

34.6%

Computation of capital employed

   
     
 

Year Ended

March 31, 2023

Year Ended

March 31, 2022

Property Plant and Equipment

66,462

62,169

Intangibles

30,849

27,246

Goodwill

4,245

4,418

Investment in equity accounted associates

4,702

4,318

Other Current Assets

20,069

13,902

Other investments

660

3,668

Other non-current assets

800

894

Inventories

48,670

50,884

Trade Receivables

72,485

66,818

Derivative Financial Instruments

1,095

1,427

Less:

   

Other Liabilities

42,320

36,414

Provisions

5,513

4,315

Trade payables

26,444

25,572

Operating Capital Employed

1,75,760

1,69,443

Average Capital Employed

1,72,602

Computation of EBITDA

Refer page no. 2 and 4 for EBITDA computations.

Earnings Call Details (07:30 pm IST, 10:00 am EDT, May 10, 2023)

The management of the Company will host an earnings call to discuss the Company’s financial performance and answer any questions from the participants.

Conference Joining Information

Option 1: Express Join with DiamondPass™

Pre-register with the below link and join without waiting for the operator.
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=8728481&linkSecurityString=2cca7c8d18

Option 2: Join through below Dial-In Numbers

Universal Access Number:

+91 22 6280 1219

+91 22 7115 8120

International Toll Free Number:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

Play Back: The play back will be available after the earnings call, till May 17th, 2023. For play back dial in phone No: +91 22 7194 5757, and Playback Code is 65827.

Transcript: Transcript of the Earnings call will be available on the Company’s website: www.drreddys.com

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2022. The company assumes no obligation to update any information contained herein.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005650/en/

Contacts

INVESTOR RELATIONS
RICHA PERIWAL
richaperiwal@drreddys.com

MEDIA RELATIONS
USHA IYER
ushaiyer@drreddys.com

Source: Dr. Reddy’s Laboratories Ltd.

Smart Multimedia Gallery

Q4 FY23 Sales Mix (Graphic: Business Wire)

FY23 Sales Mix (Graphic: Business Wire)

Powered by Business Wire

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20230510005650/en

Back to news